Navigation Links
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical Femur Fracture in Half
Date:2/8/2012

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is growing evidence that supports an association between atypical fractures of the femur – a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis. While the risk for suffering an atypical femur fracture while taking bisphosphonates is still very small – just 1 in 1,000 patients after six years of treatment – research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that discontinuing bisphosphonate use following an atypical femur fracture can significantly lower the risk for a subsequent atypical fracture.

Scientists believe that bisphosphonates may suppress the body's natural process of remodeling – where old bone tissue is replaced with new, healthy tissue – in some patients, resulting in brittle bones susceptible to atypical fractures, especially in the femur.

Investigators reviewed femur fracture data from Jan. 1, 2007 until Dec. 31, 2009 in patients older than 45 enrolled in a large California HMO. There were 126 patients with an atypical femur fracture who reportedly took bisphosphonates prior to their bone break.

The incidence of a subsequent atypical femur fracture occurring in the other thigh was 53.9 percent in patients who continued bisphosphonates for three or more years after their first fracture, compared to 19.3 percent in patients who discontinued bisphosphonate use. Overall, subsequent atypical femur fractures were decreased by 65.6 percent when bisphosphonates were stopped within one year following the first fracture.

"The risk of a contralateral atypical femur fracture (on the opposite side) increases over time if the bisphosphonates are continued," said lead investigator Richard Dell, MD, a researcher in the Department of Orthopaedics at Kaiser Permanente. "Based on these observations, we recommend discontinuing bisphosphonate use as soon as possible after the initial atypical femur fracture has occurred."  

Dr. Dell then recommends the ongoing evaluation of these patients, through X-ray or MRI, as they still are at risk for a subsequent, atypical femur fracture on the other femur.

If the patient is at high risk for other fractures, the study recommends use of an alternative osteoporosis medication.

Disclosure:  The author of this study does not have anything related to disclose.

Study Abstract

About  AAOS

Follow us on Facebook.com/AAOS1 and Twitter.com/AAOS1

For more information on bone and joint health, visit Orthoinfo.org.


'/>"/>
SOURCE American Academy of Orthopaedic Surgeons
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015
2. Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
3. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
4. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
5. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
6. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
7. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
8. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
9. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
10. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
11. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
(Date:2/11/2016)... Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% ... ALEX is said to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out ...
(Date:2/11/2016)... ANKENY, Iowa , Feb. 11, 2016  Proliant ... New Zealand Bovine Serum Albumin (BSA) manufacturing facility.  The ... New Zealand , in Feilding. ... installation was done to functionally duplicate the systems in ... the same vendors used for U.S. installations.  ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... , ... February 11, 2016 , ... “ HEALING MIND ... through a Well Managed Mind” (published by Balboa Press) teaches readers how to become ... being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how ...
(Date:2/11/2016)... ... February 11, 2016 , ... SPH Analytics ... action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its primary care ... healthcare system. Details of the contract were not disclosed. , As the healthcare ...
(Date:2/11/2016)... ... February 11, 2016 , ... Registered nurses, licensed practical nurses and nursing aides ... Time to Act, Time to Heal” on Thursday, February 25 from 9:00 to 11:00 ... is Vishal Chedda, president of ANSA Consultants, who will discuss clinical best practices throughout ...
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health ... the St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but ... exhibit, the MEGA Heart, prior to the game. The MEGA Heart will be located ...
Breaking Medicine News(10 mins):